sorafenib has been researched along with naphthoquinones in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (naphthoquinones) | Trials (naphthoquinones) | Recent Studies (post-2010) (naphthoquinones) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7,110 | 149 | 2,923 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Go, ML; Huynh, H; Sim, MY; Yuen, JSP | 1 |
| Cui, Y; Feng, W; Liu, S; Liu, Y; Rong, L; Shao, X; Shi, W; Wang, Z; Zhang, H | 1 |
| Eguchi, Y; Iino, S; Kageyama, R; Morimoto, M; Nakamura, S; Okusaka, T | 1 |
1 trial(s) available for sorafenib and naphthoquinones
| Article | Year |
|---|---|
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Hepatocellular; East Asian People; Humans; Liver Neoplasms; Naphthoquinones; Sorafenib | 2023 |
2 other study(ies) available for sorafenib and naphthoquinones
| Article | Year |
|---|---|
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzyme CYLD; Dose-Response Relationship, Drug; Drug Combinations; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Inhibitor of Differentiation Protein 1; Kidney Neoplasms; Male; Mice; Mice, SCID; Naphthoquinones; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Signal Transduction; Sorafenib; Survivin; Tumor Suppressor Proteins; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2017 |
Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification.
Topics: Cell Line, Tumor; Ferric Compounds; Ferroptosis; Glutathione; Hydrogen Peroxide; Nanomedicine; Naphthoquinones; Sorafenib | 2022 |